NAV

Mitoguazone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mitoguazone
DrugBank Accession Number
DB12967
Background

Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 184.2024
Monoisotopic: 184.118492424
Chemical Formula
C5H12N8
Synonyms
  • Me-GAG
  • Methyl-G
  • Mitoguazona
  • Mitoguazone
  • Mitoguazonum
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Mitoguazone is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Mitoguazone is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Mitoguazone is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Mitoguazone is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Mitoguazone is combined with Bupivacaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Mitoguazone dihydrochlorideNNI098FX5Q7059-23-6VVTBQCXLZQYGQE-PVTAQEPXSA-N

Categories

ATC Codes
L01XX16 — Mitoguazone
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
OD5Q0L447W
CAS number
459-86-9
InChI Key
MXWHMTNPTTVWDM-NXOFHUPFSA-N
InChI
InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
IUPAC Name
N''-[(E)-[(1E)-1-{[(diaminomethylidene)amino]imino}propan-2-ylidene]amino]guanidine
SMILES
C\C(\C=N\N=C(N)N)=N/N=C(N)N

References

General References
Not Available
PubChem Compound
5351154
PubChem Substance
347829107
ChemSpider
4508218
ChEBI
43996
ChEMBL
CHEMBL216913
ZINC
ZINC000004557060
PDBe Ligand
MGB
Wikipedia
Mitoguazone
PDB Entries
1i7c

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentLymphoma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.412 mg/mLALOGPS
logP0.93ALOGPS
logP-2.2Chemaxon
logS-2.6ALOGPS
pKa (Strongest Acidic)16.46Chemaxon
pKa (Strongest Basic)7.38Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area153.52 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity48.85 m3·mol-1Chemaxon
Polarizability18.58 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-d2e6fc03104b8ba98d49
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001l-1900000000-0b6f4f75a59b76d09672
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-003u-9600000000-a727f4617e21262d6d8f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-9200000000-da6629a5b635592353f6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001m-9200000000-5608cf7add5403a7e9d0
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0005-9000000000-dc6923ab8c910d6f6bc9
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-148.08363
predicted
DeepCCS 1.0 (2019)
[M+H]+150.44165
predicted
DeepCCS 1.0 (2019)
[M+Na]+156.67009
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 01:38 / Updated at January 14, 2023 19:02